Your browser does not support JavaScript! CICLOPIROX OLAMINE CREAM [PERRIGO NEW YORK INC]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

CICLOPIROX OLAMINE cream
[Perrigo New York Inc]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL Abbreviated New Drug Application
Drug Label Sections

For Dermatologic Use Only

Not For Use In Eyes

Rx Only

DESCRIPTION

Ciclopirox Olamine Cream USP, 0.77% is for topical use. Each gram of Ciclopirox Olamine Cream USP, 0.77% contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible, vanishing cream base consisting of benzyl alcohol (1% as a preservative), cetyl alcohol, lactic acid, light mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate, and stearyl alcohol.

Ciclopirox Olamine Cream USP, 0.77% contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone,2-aminoethanol salt.

The CAS Registry Number is 41621-49-2. The chemical structure is:

Chemical Structure Image

Ciclopirox Olamine Cream USP, 0.77% has a pH of 7.

CLINICAL PHARMACOLOGY

Ciclopirox is a broad-spectrum, antifungal agent that inhibits the growth of pathogenic dermatophytes, yeasts, and Malassezia furfur. Ciclopirox exhibits fungicidal activity in vitro against isolates of Trichophytonrubrum, Trichophytonmentagrophytes, Epidermophytonfloccosum, Microsporumcanis, and Candida albicans.

Pharmacokinetic studies in men with tagged ciclopirox solution in polyethylene glycol 400 showed an average of 1.3% absorption of the dose when it was applied topically to 750 cm2 on the back followed by occlusion for 6 hours. The biological half-life was 1.7 hours and excretion occurred via the kidney. Two days after application only 0.01% of the dose applied could be found in the urine. Fecal excretion was negligible.

Penetration studies in human cadaverous skin from the back, with ciclopirox olamine cream with tagged ciclopirox showed the presence of 0.8 to 1.6% of the dose in the stratum corneum 1.5 to 6 hours after application. The levels in the dermis were still 10 to 15 times above the minimum inhibitory concentrations.

Autoradiographic studies with human cadaverous skin showed that ciclopirox penetrates into the hair and through the epidermis and hair follicles into the sebaceous glands and dermis, while a portion of the drug remains in the stratum corneum.

Draize Human Sensitization Assay, 21-Day Cumulative Irritancy study, Phototoxicity study, and Photo-Draize study conducted in a total of 142 healthy male subjects showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity, and no photo-contact sensitization due to ciclopirox olamine cream.

INDICATIONS AND USAGE

Ciclopirox Olamine Cream USP, 0.77% is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophytonrubrum, Trichophytonmentagrophytes, Epidermophytonfloccosum, and Microsporumcanis; candidiasis (moniliasis)due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur.

CONTRAINDICATIONS

Ciclopirox Olamine Cream USP, 0.77% is contraindicated in individuals who have shown hypersensitivity to any of its components.

WARNINGS

General - Ciclopirox Olamine Cream USP, 0.77% is not for ophthalmic use.

Keep out of reach of children.

PRECAUTIONS

If a reaction suggesting sensitivity or chemical irritation should occur with the use of Ciclopirox Olamine Cream USP, 0.77%, treatment should be discontinued and appropriate therapy instituted.

Information for Patients

The patient should be told to:

1.
Use the medication for the full treatment time even though symptoms may have improved and notify the physician if there is no improvement after four weeks.
2.
Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible sensitization.
3.
Avoid the use of occlusive wrappings or dressings.

Carcinogenesis, Mutagenesis, Impairment of Fertility -

A carcinogenicity study in female mice dosed cutaneously twice per week for 50 weeks followed by a 6-month drug-free observation period prior to necropsy revealed no evidence of tumors at the application site.

The following in vitro and in vivo genotoxicity tests have been conducted with ciclopirox olamine: studies to evaluate gene mutation in the Ames Salmonella/MammalianMicrosome Assay (negative) and Yeast Saccharomyces Cerevisiae Assay (negative) and studies to evaluate chromosome aberrations in vivo in the Mouse Dominant Lethal Assay and in the Mouse Micronucleus Assay at 500 mg/kg (negative).

The following battery of in vitro genotoxicity tests were conducted with ciclopirox: a chromosome aberration assay in V79 Chinese Hamster Cells, with and without metabolic activation (positive); a gene mutation assay in the HGPRT - test with V79 Chinese Hamster Cells (negative); and a primary DNA damage assay (i.e., unscheduled DNA Synthesis Assay in A549 Human Cells (negative)). An in vitro Cell Transformation Assay in BALB/C3T3 Cells was negative for cell transformation. In an in vivo Chinese Hamster Bone Marrow Cytogenetic Assay, ciclopirox was negative for chromosome aberrations at 5,000 mg/kg.

Pregnancy: Category B -

Reproduction studies have been performed in the mouse, rat, rabbit, and monkey (via various routes of administration) at doses 10 times or more the topical human dose and have revealed no significant evidence of impaired fertility or harm to the fetus due to ciclopirox. There are, however, no adequate or well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers -

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Ciclopirox Olamine Cream USP, 0.77% is administered to a nursing woman.

Pediatric Use -

Safety and effectiveness in pediatric patients below the age of 10 years have not been established.

ADVERSE REACTIONS

In all controlled clinical studies with 514 patients using ciclopirox olamine cream and 296 patients using the vehicle cream, the incidence of adverse reactions was low. This included pruritus at the site of application in one patient and worsening of the clinical signs and symptoms in another patient using ciclopirox olamine cream and burning in one patient and worsening of the clinical signs and symptoms in another patient using the vehicle cream.

DOSAGE AND ADMINISTRATION

Gently massage Ciclopirox Olamine Cream USP, 0.77% into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Cream USP, 0.77% the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.

HOW SUPPLIED

Ciclopirox Olamine Cream USP, 0.77% is available as follows:

15 g tube (NDC 45802-138-35)

30 g tube (NDC 45802-138-11)

90 g tube (NDC 45802-138-18)

STORAGE

Store at 20-25ºC (68-77ºF) [see USP Controlled Room Temperature].

Manufactured By Perrigo

Bronx, NY 10457

Distributed By Perrigo

Allegan, MI 49010 • www.perrigo.com

Rev. 12/12

:2T200 RC J3

Principal Display Panel - 15 g Carton

Rx Only

Ciclopirox Olamine Cream USP, 0.77%

For Dermatologic Use Only. Not For Use In Eyes.

Ciclopirox Olamine Cream USP, 0.77% - 15 g  Carton

Principal Display Panel - 15 g Tube

Rx Only

Ciclopirox Olamine Cream USP, 0.77%

For Dermatologic Use Only. Not For Use In Eyes.

Ciclopirox Olamine Cream USP, 0.77% - 15 g  Tube
CICLOPIROX OLAMINE 
ciclopirox olamine cream
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:45802-138
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CICLOPIROX OLAMINE (CICLOPIROX) CICLOPIROX7.7 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
BENZYL ALCOHOL 
CETYL ALCOHOL 
LACTIC ACID 
LIGHT MINERAL OIL 
MYRISTYL ALCOHOL 
OCTYLDODECANOL 
POLYSORBATE 60 
WATER 
SORBITAN MONOSTEARATE 
STEARYL ALCOHOL 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:45802-138-351 in 1 CARTON
115 g in 1 TUBE
2NDC:45802-138-111 in 1 CARTON
230 g in 1 TUBE
3NDC:45802-138-181 in 1 CARTON
390 g in 1 TUBE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07736407/19/2006
Labeler - Perrigo New York Inc (078846912)

Revised: 3/2013
 
Perrigo New York Inc

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services